Uncategorized

Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s Voyxact

Published

on

Otsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated approval last month, showed “impressive” stabilization, analysts say.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version